Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial - Pöschel, Viola; Held, Gerhard Wolfgang; Ziepert, Marita; Witzens-Harig, Mathias; Holte, Harald; Thurner, Lorenz; Borchmann, Peter; Viardot, Andreas; Sökler, Martin; Keller, Ulrich; Schmidt, Christian; Truemper, Lorenz; et al. (The lancet, 2019)
Gesehen am 30.04.2020